TG4010

BIOLOGICAL3 trials

Sponsors

Transgene, Megan Daly, MD

Conditions

Non Small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaRecurrent Non-Small Cell Lung CarcinomaStage I Non-Small Cell Lung CancerStage II Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer

Phase 2

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

TerminatedNCT01383148

TransgeneNon-Small-Cell Lung Carcinoma

Start: 2012-04-30End: 2016-07-31Updated: 2017-01-05

TG4010 and Nivolumab in Patients With Lung Cancer

CompletedNCT02823990

Megan Daly, MDRecurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer +3

Start: 2016-12-14End: 2021-02-24Updated: 2025-11-07

A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT03353675

TransgeneNon Small Cell Lung Cancer Metastatic

Start: 2018-01-05End: 2021-02-17Updated: 2022-01-11

Related Papers

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

2026-09-02

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Journal for ImmunoTherapy of Cancer2017-09-0263 citations

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

2015-12-23155 citations

Abstract 2498: The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies

Cancer Research2015-08-01

Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.

Journal of Clinical Oncology2015-05-208 citations